AMGEN INC (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Open AMGEN INC in the interactive graph- Ticker
- AMGN
- SEC CIK
- 0000318154
- Sector
- Health Care
- Industry
- Biotechnology
- Periods
- FY2025 Q1, FY2026, FY2026 Q1, FY2026 Q3, FY2027
- Headquarters
- Thousand Oaks, CA
- Employees
- 31,500
Key figures
- Revenue 8.60B USD
- NetIncome 1.82B USD
- DilutedEPS 3.34 USD/share
Reported figures
- BasicEPS 3.22 USD/share
- BasicEPS 3.37 USD/share
- BasicSharesOutstanding 538.00M count
- BasicSharesOutstanding 540.00M count
- CapitalExpenditure 400.00M USD
- CapitalExpenditure 700.00M USD
- CapitalExpenditure 712.00M USD
- CashAndEquivalents 12.00B USD
- CostOfRevenue 1.42B USD
- CostOfRevenue 1.60B USD
- CostOfRevenue 2.74B USD
- CostOfRevenue 2.97B USD
- DilutedEPS 3.20 USD/share
- DilutedEPS 3.34 USD/share
- DilutedEPS 4.90 USD/share
- DilutedEPS 5.15 USD/share
- DividendPerShare 2.52 USD/share
- FreeCashFlow 1.00B USD
- FreeCashFlow 1.48B USD
- FreeCashFlow 1.50B USD
- GrossProfit 5.87B USD
- InterestExpense 657.00M USD
- InterestExpense 723.00M USD
- NetIncome 1.73B USD
- NetIncome 1.82B USD
- NetIncome 2.65B USD
- NetIncome 2.80B USD
- OperatingCashFlow 1.40B USD
- OperatingCashFlow 2.20B USD
- OperatingExpenses 5.95B USD
- OperatingExpenses 6.97B USD
- OperatingIncome 1.18B USD
- OperatingIncome 1.20B USD
- OperatingIncome 2.67B USD
- OperatingIncome 2.70B USD
- OperatingIncome 3.60B USD
- OperatingIncome 3.70B USD
- OperatingMargin 15 percent
- OperatingMargin 32.4 percent
- OperatingMargin 45.3 percent
- and 22 more in the interactive graph
Guidance
- CapitalExpenditure guidance 2.60B USD
- DilutedEPS guidance 15.62–17.10 USD/share
- DilutedEPS guidance 21.70–23.10 USD/share
- OtherMetric guidance 14.5–16 percent
- OtherMetric guidance 15–16.5 percent
- OtherMetric guidance 3.00B USD
- Revenue guidance 37.10B–38.50B USD
Drivers
- AMJEVITA/AMGEVITA sales increased primarily driven by 18% higher net selling price and 8%
- BLINCYTO sales increased driven by 19% volume growth, partially offset by unfavorable chan
- EVENITY sales increased driven by volume growth
- Enbrel sales decreased primarily driven by unfavorable changes to estimated sales deductio
- Established products sales increased driven by 10% higher net selling price, partially off
- Free cash flow increased driven by business performance and timing of working capital, par
- GAAP Cost of Sales as a percentage of product sales decreased driven by lower amortization
- GAAP EPS increased driven by higher operating income, partially offset by net unrealized l
- GAAP Other operating income for the first quarter included litigation settlements
- GAAP R&D expenses increased driven by higher spend in Later-Stage Clinical Programs, inclu
- GAAP SG&A expenses decreased driven by lower general and administrative expenses, partiall
- IMDELLTRA/IMDYLLTRA sales increased driven by volume growth
- KRYSTEXXA sales increased primarily driven by 20% higher net selling price, partially offs
- KYPROLIS sales increased primarily driven by higher net selling price
- LUMAKRAS/LUMYKRAS sales increased driven by volume growth
- MVASI sales decreased driven by 8% lower net selling price and 7% unfavorable changes to e
- Non-GAAP Cost of Sales as a percentage of product sales increased driven by higher profit
- Non-GAAP EPS increased driven by higher revenues, partially offset by higher operating exp
- Non-GAAP R&D expenses increased driven by higher spend in Later-Stage Clinical Programs, i
- Non-GAAP SG&A expenses decreased driven by lower general and administrative expenses, part
- Nplate sales increased driven by 8% volume growth and higher net selling price, excluding
- Otezla sales decreased as 8% lower net selling price and 2% lower volume were offset by fa
- PAVBLU sales increased driven by 16% volume growth, partially offset by 9% from lower inve
- Prolia sales decreased primarily driven by 17% lower volume, 10% lower net selling price,
- Repatha sales increased driven by 35% volume growth and 8% favorable changes to estimated
- Sixteen products delivered at least double-digit sales growth in the first quarter
- TAVNEOS sales increased driven by 55% volume growth, partially offset by 15% from lower in
- TEPEZZA sales increased driven by a 22% impact from higher inventory levels and higher net
- TEZSPIRE sales increased driven by 32% volume growth, partially offset by 8% from lower in
- Total revenues increased driven by 9% volume growth, partially offset by 2% lower net sell
- UPLIZNA sales increased primarily driven by volume growth
- Vectibix sales increased driven by 11% volume growth, partially offset by lower inventory
- XGEVA sales decreased driven by 19% lower volume and lower net selling price
Risks
- Cases of vanishing bile duct syndrome (VBDS) have been reported with TAVNEOS, largely from
- Enbrel net selling price decline reflects the impact of U.S. Medicare Part D price setting
- FDA's CDER issued a proposal to withdraw approval of TAVNEOS, asserting that there is new
- Hepatotoxicity is a known risk of TAVNEOS treatment for AAV and has been a subject of ongo
- Prolia sales expected to experience accelerated sales erosion driven by increased competit
- XGEVA sales expected to experience accelerated sales erosion driven by increased competiti
Corporate events
- The Company declared a first quarter 2026 dividend of $2.52 per share that was paid on Mar
Quotes
- “Our first quarter results demonstrate the strength of our business, with 16 bran…”